We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch® biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

Our Publications on EpiSwitch®

A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.

Jakub, JW., et. al.,
Melanoma Research

October 3, 2015

https://www.ncbi.nlm.nih.gov/pubmed/26225582

FC-g Receptor Targeting Reduces Bone Disease in a Pre-clinical Model of Multiple Myeloma

Williams, et. al.,
American Society of Haematology

September 12, 2015

https://www.oxfordbiodynamics.com/wp-content/uploads/2021/03/2015-ASH-Fcg-receptor-targeting-reduces-bone-diseases.pdf

Chromatin barcodes as biomarkers for melanoma.

Bastonini, E., et. al.,
Pigment Cell Melanoma Research

September 3, 2014

https://www.ncbi.nlm.nih.gov/pubmed/24807349

A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).

Lim, EH., et. al.,
J Clinical Oncology

May 30, 2014

http://meetinglibrary.asco.org/content/133682-144

Chromatin signatures of DLBCL subtypes.

Field, et. al.,
Cancer Research

April 5, 2014

http://cancerres.aacrjournals.org/content/74/19_Supplement/462

Current Advances in Epigenetics.

Hunter, et., al.,
Clinical and Statistical Consideration in Personalized Medicine

March 27, 2014

http://www.oxfordbiodynamics.com/2014/03/27/current-advances-in-epigenetics/

Formation of distinct chromatin conformation signatures epigenetically regulate macrophage activation.

Mukhopadhyay, et. al.,
International Immunopharmacology

January 3, 2014

https://www.ncbi.nlm.nih.gov/pubmed/24211766

Validation of a new Epigenetic-based Prognostic Blood test to predict Prostate Cancer Aggressiveness

Pchejetski, D, et. al.,
Annals of Oncology

November 1, 2013

http://doi:10.1093/annonc/mdt459.36

Development of novel ALS treatment on the basis of mechanisms of cellular chronological life span control.

Youdell, M., et.al.,
12th Annual Northeast Amyotrophic Lateral Sclerosis Consortium

October 3, 2013

http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALS-POSTER.pdf

A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Tan, Y., et. al.,
J Clinical Oncology

May 31, 2013

http://meetinglibrary.asco.org/content/113789-132